AU2013352406A1 - Combination therapy - Google Patents

Combination therapy Download PDF

Info

Publication number
AU2013352406A1
AU2013352406A1 AU2013352406A AU2013352406A AU2013352406A1 AU 2013352406 A1 AU2013352406 A1 AU 2013352406A1 AU 2013352406 A AU2013352406 A AU 2013352406A AU 2013352406 A AU2013352406 A AU 2013352406A AU 2013352406 A1 AU2013352406 A1 AU 2013352406A1
Authority
AU
Australia
Prior art keywords
combination
inhibitor
cancer
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013352406A
Other languages
English (en)
Inventor
Shivang Doshi
Sunkyu Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2013352406A1 publication Critical patent/AU2013352406A1/en
Priority to AU2016262781A priority Critical patent/AU2016262781A1/en
Priority to AU2018200323A priority patent/AU2018200323A1/en
Priority to AU2019200881A priority patent/AU2019200881A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013352406A 2012-11-28 2013-11-25 Combination therapy Abandoned AU2013352406A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2016262781A AU2016262781A1 (en) 2012-11-28 2016-11-25 Combination therapy
AU2018200323A AU2018200323A1 (en) 2012-11-28 2018-01-15 Combination therapy
AU2019200881A AU2019200881A1 (en) 2012-11-28 2019-02-08 Combination therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730661P 2012-11-28 2012-11-28
US61/730,661 2012-11-28
PCT/US2013/071659 WO2014085318A1 (en) 2012-11-28 2013-11-25 Combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016262781A Division AU2016262781A1 (en) 2012-11-28 2016-11-25 Combination therapy

Publications (1)

Publication Number Publication Date
AU2013352406A1 true AU2013352406A1 (en) 2015-06-04

Family

ID=49753505

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2013352406A Abandoned AU2013352406A1 (en) 2012-11-28 2013-11-25 Combination therapy
AU2016262781A Abandoned AU2016262781A1 (en) 2012-11-28 2016-11-25 Combination therapy
AU2018200323A Abandoned AU2018200323A1 (en) 2012-11-28 2018-01-15 Combination therapy
AU2019200881A Ceased AU2019200881A1 (en) 2012-11-28 2019-02-08 Combination therapy

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2016262781A Abandoned AU2016262781A1 (en) 2012-11-28 2016-11-25 Combination therapy
AU2018200323A Abandoned AU2018200323A1 (en) 2012-11-28 2018-01-15 Combination therapy
AU2019200881A Ceased AU2019200881A1 (en) 2012-11-28 2019-02-08 Combination therapy

Country Status (12)

Country Link
US (1) US9408847B2 (enExample)
EP (1) EP2925365A1 (enExample)
JP (2) JP2016501221A (enExample)
KR (1) KR20150089053A (enExample)
CN (1) CN104812414A (enExample)
AU (4) AU2013352406A1 (enExample)
BR (1) BR112015012197A8 (enExample)
CA (1) CA2891938A1 (enExample)
HK (1) HK1211475A1 (enExample)
MX (1) MX2015006809A (enExample)
RU (1) RU2015125307A (enExample)
WO (1) WO2014085318A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013502697A1 (en) * 2011-07-01 2014-02-10 Novartis Ag Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
CN105473140B (zh) 2013-03-15 2018-04-10 G1治疗公司 在化学疗法期间对正常细胞的瞬时保护
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR20240110004A (ko) 2014-03-14 2024-07-12 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CA2943611A1 (en) 2014-03-28 2015-10-01 Duke University Method of treating cancer using selective estrogen receptor modulators
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
JP2017535528A (ja) 2014-10-03 2017-11-30 ノバルティス アーゲー 組み合わせ治療
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
JP6692826B2 (ja) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
CN106336412A (zh) * 2015-07-10 2017-01-18 南开大学 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3156406A1 (en) * 2015-10-14 2017-04-19 ratiopharm GmbH Crystalline forms of ribociclib free base
HRP20220436T1 (hr) 2015-11-03 2022-05-27 Janssen Biotech, Inc. Protutijela koja se specifično vežu na pd-1 i njihove uporabe
CA3007671A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
MX389702B (es) * 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
IL269357B2 (en) * 2017-03-16 2024-10-01 Eisai R&D Man Co Ltd A combination of ER? inhibitor and CDK 4/6 inhibitor for use in a method of treating breast cancer
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3641812A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
TWI750539B (zh) * 2018-11-23 2021-12-21 大陸商蘇州亞盛藥業有限公司 新穎藥物組成物及其用途
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2689177T3 (es) * 2010-04-13 2018-11-08 Novartis Ag Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer

Also Published As

Publication number Publication date
MX2015006809A (es) 2015-08-06
EP2925365A1 (en) 2015-10-07
WO2014085318A1 (en) 2014-06-05
JP2016501221A (ja) 2016-01-18
AU2018200323A1 (en) 2018-02-01
JP2019031500A (ja) 2019-02-28
CA2891938A1 (en) 2014-06-05
BR112015012197A2 (pt) 2017-07-11
KR20150089053A (ko) 2015-08-04
BR112015012197A8 (pt) 2019-10-01
CN104812414A (zh) 2015-07-29
HK1211475A1 (en) 2016-05-27
US20150306104A1 (en) 2015-10-29
US9408847B2 (en) 2016-08-09
AU2019200881A1 (en) 2019-02-28
AU2016262781A1 (en) 2016-12-15
RU2015125307A (ru) 2017-01-10

Similar Documents

Publication Publication Date Title
US9408847B2 (en) Combination therapy
US20250177402A1 (en) Combination therapy for the treatment of cancer
CN108348522A (zh) 含(a)周期素依赖性激酶4/6(cdk4/6)抑制剂lee011(＝ribociclib)和(b)表皮生长因子受体(egfr)抑制剂厄洛替尼的药物组合，用于治疗或预防癌症
TW201412316A (zh) 醫藥組合
US20210186973A1 (en) Combination of ribociclib and dabrafenib for treating or preventing cancer
Thotala et al. A new class of molecular targeted radioprotectors: GSK-3β inhibitors
CN110652514A (zh) 第三代egfr抑制剂的制药用途
US20220257571A1 (en) Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations
Chen et al. VS-5584, a PI3K/mTOR dual inhibitor, exerts antitumor effects on neuroblastomas in vitro and in vivo
KR20160090814A (ko) Jak, cdk 및 pim의 억제제를 포함하는 조합 요법
US20180318275A1 (en) Combination therapy using pi3k inhibitor and mdm2 inhibitor
US10328065B2 (en) Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
RU2805145C2 (ru) Комбинированная терапия для лечения рака
阿賀康弘 Novel Oral Derivative UD-017, a Highly Selective CDK7 Inhibitor, Exhibits Anticancer Activity by Inducing Cell-Cycle Arrest and Apoptosis in Human Colorectal Cancer
JP2018526375A (ja) 組み合わせ療法

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted